Yasmyne Ronquillo, M.D. Ophthalmology Medicare: Medicare Enrolled Practice Location: 1180 N Monroe St, Monroe, MI 48162 Phone: 734-243-5300 Fax: 734-243-3236 |
Dr. Meiraj Ahmad Siddiqui, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 725 N Monroe St, Monroe, MI 48162 Phone: 734-242-2727 Fax: 734-242-2745 |
Dr. Stephen Y Reed, M.D. Ophthalmology Medicare: Medicare Enrolled Practice Location: 1036 Abbey Rd, Monroe, MI 48161 Phone: 734-457-6580 |
Manal Peracha-riyaz, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 725 N Monroe St, Monroe, MI 48162 Phone: 734-242-2727 Fax: 734-242-2745 |
Mandar M Joshi, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1180 N Monroe St, Monroe, MI 48162 Phone: 734-243-5300 Fax: 734-243-3236 |
Zuhair H Peracha, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 725 N Monroe St, Monroe, MI 48162 Phone: 734-242-2727 Fax: 734-242-2745 |
News Archive
Pancreatic cancer is the fourth leading cause of cancer-related death for both men and women in the United States. As the prevalence of overweight and obesity have rapidly increased during the last 2 decades, accumulating evidence has emerged that excess body weight is a risk factor for pancreatic cancer.
The American Medical Society for Sports Medicine releases its latest position statement, "Concussion in Sport," which recommends healthcare professionals apply a more individualized approach in the diagnosis and care management of sports concussion, a traumatic head injury with a reported 3.8 million occurrences per year.
According to new research the PSA test for prostate cancer does more harm than good. This week, the United States Preventive Services Task Force is expected to announce its recommendation against routine testing for blood levels of prostate-specific antigen, the protein that can be a signal of prostate cancer.
Teva Pharmaceutical Industries Ltd. announced today that the U.S. District Court for the District of Delaware has issued a decision in its litigation over the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Takeda Pharmaceuticals North America, Inc.'s Prevacid® (Lansoprazole) SoluTab.
AbbVie released interim results from an ongoing Phase 2 study of its investigational compound veliparib in combination with chemotherapy, which showed a 35 percent improvement (P-value=0.14) in progression-free survival (PFS) and a 30 percent improvement (P-value=0.21) in overall survival (OS) in patients with previously untreated metastatic or advanced non-small cell lung cancer (NSCLC).
› Verified 6 days ago